Physician profile
Nancy Love
NPI 1427332030
$793.84
in general payments reported to CMS, 2019-2025
10 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.48 · 2020: $38.12 · 2023: $193 · 2024: $120 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $339.57 | 2023-2025 | Tepezza, Repatha, Repatha |
| Abbott Laboratories | $136.67 | 2023 | Freestyle Libre 3 |
| Medtronic, INC. | $118.88 | 2025 | Signia |
| Astrazeneca Pharmaceuticals Lp | $50.47 | 2020-2025 | Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $43.59 | 2019-2020 | |
| Novo Nordisk INC | $30.18 | 2023-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $21.94 | 2019 | |
| Pfizer INC. | $20.36 | 2019 | |
| Corcept Therapeutics | $17.90 | 2025 | Korlym |
| Lilly USA, LLC | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Love listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.